Clinical trials: Obese Women
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Overweight
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women
The purpose of this study is to examine the effectiveness of the South Beach Diet™ and South Beach Diet™ products compared to a traditional calorie restricted diet.
- Trial name
- NCT00932516
- Testing
- South Beach Diet™ with South Beach Diet™ Products, South Beach Diet™, Calorie restricted diet with South Beach Diet™ Products
- Where
- 4 sites in United States
- Volunteers
- 248 people
- Sponsor
- Mondelēz International, Inc.
Obesity, Obesity, Abdominal
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
Forty women aged between 18 and 75 years-old with a BMI> 30kg/m2 are recruited to participate in the evaluation of their medical management.
- Conditions
- Obesity, Obesity, Abdominal, Obesity, Visceral, Female
- Trial name
- PPAR-NAPAS (NCT04436419)
- Testing
- Alpha lipoic acid (plus full hospitalization)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Fauqué
Insulin Resistance
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet).
- Trial name
- NCT00162799
- Testing
- Triflusal (DCI)
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Obesity
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
- Trial name
- NCT04890873
- Testing
- ERX1000
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- ERX Pharmaceuticals
Metabolism and Nutrition Disorder, Obesity
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for…
- Trial name
- NCT02870231
- Testing
- NNC9204-0530, liraglutide
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Primary Objective: To assess in overweight to obese subjects the change in sleep energy expenditure after repeated subcutaneous (SC) doses of SAR425899.
- Trial name
- NCT03376802
- Testing
- SAR425899
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Polycystic Ovary Syndrome
Combination of D-chiro-inositol With Ketogenic Diet
The study aims to evaluate whether the combination of a product based on D-chiro-inositol and the ketogenic diet can improve the metabolic/endocrine picture of overweight/obese women with PCOS, with insulin resistance, in a…
- Trial name
- NCT05348967
- Testing
- TECADRIOL
- Where
- Italy
- Sponsor
- Lo.Li.Pharma s.r.l
Healhty, Overweight or Obesity
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812…
- Trial name
- NCT07224399
- Testing
- BGM1812
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Overweight, Obesity
Dietary Supplementation on Fat Oxidation
The purpose of this pilot study is to evaluate the effects of 4 weeks of daily consumption of encapsulated N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT) at a dose of 120 mg/d on measures of fat oxidation in…
- Trial name
- NCT06548048
- Testing
- Dietary supplement containing plant derived phenolics, Microcrystaline cellulose
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brightseed
Urinary Incontinence,Stress
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have…
- Trial name
- RESTRAIN-SUI (NCT07202884)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Canada and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Healthy, Obesity
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product [formulation A]) and in a vial (test product [formulation B2]) in male and female trial participants…
- Trial name
- NCT07768813
- Testing
- Survodutide formulation A, Survodutide formulation B2
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
This study medicine NNC0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes.
- Trial name
- NCT06461039
- Testing
- NNC0487-0111 A, NNC0487-0111 C, Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Body Weight Changes
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120).
- Conditions
- Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise
- Trial name
- PHAEOSOL-ONE (NCT04761406)
- Testing
- Phaeosol group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Microphyt
Healthy Participants
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol…
- Trial name
- NCT07013643
- Testing
- AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP)
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women
The purpose of this study is to examine the effectiveness of the South Beach Diet and products compared to the American Diabetic Association Diabetes Meal Plan.
- Trial name
- NCT00931034
- Testing
- South Beach Diet with South Beach Diet Products, American Diabetes Association Diabetes Meal Plan
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Mondelēz International, Inc.
Obesity, Healthy Volunteers
Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants
The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and…
- Trial name
- NCT06106334
- Testing
- S309309, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obese
Metabolism Associated With Abdominal Fat Mass Distribution
Objectives: The primary objective of this clinical trial is to characterize metabolic signatures associated with abdominal fat distribution in 40 women with different BMI 29-40 and different abdominal distribution of fat…
- Trial name
- NCT01726647
- Where
- 2 sites in Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Overweight
Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women
Before and after study in obese women 25-35 years old, BMI 30-35, taking Strath® Kräuterhefe Original (liquid), Herbal Yeast Food Supplement for three weeks.
- Trial name
- NCT03223987
- Testing
- Strath® Kräuterhefe Original (liquid)
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bio-Strath AG